Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action

Neuron

Volumn 19, Issue 6, 1997, Pages 1271-1283

  Fon, Edward A ^a   Pothos, Emmanuel N ^b   Sun, Bao Cun ^b   Killeen, Nigel ^c   Sulzer, David ^b   Edwards, Robert H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Columbia University ^*  (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN MONOAMINE; DEXAMPHETAMINE; DOPAMINE; NOMIFENSINE; SODIUM CHLORIDE; TETRABENAZINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; EXOCYTOSIS; FEEDING; MEMBRANE DEPOLARIZATION; MEMBRANE TRANSPORT; MESENCEPHALON; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; STORAGE; SURVIVAL; SYNAPSE VESICLE;

EID: 0031458637     PISSN: 08966273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0896-6273(00)80418-3     Document Type: Article

References (62)

1. Alfonso, A., Grundahl, K., Duerr, J.S., Han, H.-P., and Rand, J.B. (1993). The Caenorhabditis elegans unc-17 gene: a putative vesicular acetylcholine transporter. Science 261, 617-619.
2. Amara, S.G., and Kuhar, M.J. (1993). Neurotransmitter transporters: recent progress. Annu. Rev. Neurosci. 16, 73-93.
3. Attwell, D., Barbour, B., and Szatkowski, M. (1993). Nonvesicular release of neurotransmitter. Neuron 11, 401-407.
4. Birkmayer, W., and Hornykiewicz, O. (1961). Der 1-dioxyphenylalinin-(=L-Dopa)-Effekt bei der Parkinson-Akinesie. Wien Med. Wochenschr. 73, 787-788.
5. Boadle-Biber, M.C. (1993). Regulation of serotonin synthesis. Prog. Biophys. Mol. Biol. 60, 1-15.
6. Brannan, T., Prikhojan, A., and Yahr, M.D. (1996). An in vivo comparison of the capacity of striatal versus extrastriatal brain regions to form dopamine from exogenously administered L-DOPA. J. Neural Transm. 103, 1287-1294.
7. Bruns, D., and Jahn, R. (1995). Real-time measurement of transmitter release from single synaptic vesicles. Nature 377, 62-65.
8. Cases, O., Vitalis, T., Seif, I., De Maeyer, E., Sotelo, C., and Gaspar, P. (1996). Lack of barrels in the somatosensory cortex of monoamine oxidase A-deficient mice: role of a serotonin excess during the critical period. Neuron 16, 297-307.
9. Chen, K., and Shih, J.C. (1990). Monoamine oxidase Aand B: Structure, function and behavior. In Catecholamines: Bridging Basic Science with Clinical Medicine, S. Goldstein, G. Eisenhofer, and R. McCarty, eds. (San Diego: Academic Press), pp. 292-296.
10. Cotzias, G.C., Papavasiliou, P.S., and Gellene, R. (1969). Modification of parkinsonism - chronic treatment with levodopa. N. Engl. J. Med. 180, 337-345.
11. Di Chiara, G., and Imperato, A. (1988). Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. USA 85, 5274-5278.
12. Erickson, J.D., Eiden, L.E., and Hoffman, B.J. (1992). Expression cloning of a reserpine-sensitive vesicular monoamine transporter. Proc. Natl. Acad. Sci. USA 89, 10993-10997.
13. Finn, J.P., and Edwards, R.H. (1997). Individual residues contribute to multiple differences in ligand recognition between vesicular monoamine transporters 1 and 2. J. Biol. Chem. 272, 16301-16307.
14. Fishell, G., and van der Kooy, D. (1987). Pattern formation in the striatum: developmental changes in the distribution of striatonigral neurons. J. Neurosci. 7, 1969-1978.
15. Florin, S.M., Kuczenski, R., and Segal, D.S. (1995). Effects of reserpine on extracellular caudate dopamine and hippocampus norepinephrine responses to amphetamine and cocaine: mechanistic and behavioral considerations. J. Pharmacol. Exp. Ther. 274, 231-241.
16. Frize, E.D. (1954). Mental depression in hypertensive patients treated for long periods with high doses of reserpine. N. Engl. J. Med. 251, 1006-1008.
17. Gerfen, C.R. (1992). The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia. Annu. Rev. Neurosci. 15, 285-320.
18. Gilmor, M.L., Nash, N.R., Roghani, A., Edwards, R.H., Yi, H., Hersch, S.M., and Levey, A.I. (1996). Expression of the putative vesicular acetylcholine transporter in rat brain and localization in cholinergic synaptic vesicles. J. Neurosci. 16, 2179-2190.
19. Giros, B., Jaber, M., Jones, S.R., Wightman, R.M., and Caron, M.G. (1996). Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379, 606-612.
20. Graybiel, A.M., Pickel, V.M., Joh, T.H., Reis, D.J., and Ragsdale, C.W. (1981). Direct demonstration of a correspondence between the dopamine islands and acetylcholinesterase patches in the developing striatum. Proc. Natl. Acad. Sci. USA 78, 5871-5875.
21. Johnson, R.G. (1988). Accumulation of biological amines into chromaffin granules: a model for hormone and neurotransmitter transport. Physiol. Rev. 68, 232-307.
22. Koob, G.F. (1992). Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol. Sci. 13, 177-184.
23. Krantz, D.E., Peter, D., Liu, Y., and Edwards, R.H. (1997). Phosphorylation of a vesicular monoamine transporter by casein kinase II. J. Biol. Chem. 272, 6752-6759.
24. Kumer, S.C., and Vrana, K.E. (1996). Intricate regulation of tyrosine hydroxylase activity and gene expression. J. Neurochem. 67, 443-462.
25. Lagnado, L., Gomis, A., and Job, C. (1996). Continuous vesicle cycling in the synaptic terminal of retinal bipolar cells. Neuron 17, 957-967.
26. Lebrand, C., Cases, O., Adelbrecht, C., Doye, A., Alvarez, C., El Mestikawy, S., Sief, I., and Gaspar, P. (1996). Transient uptake and storage of serotonin in developing thalamic neurons. Neuron 17, 823-835.
27. Liu, Y., and Edwards, R.H. (1997). The role of vesicular transport proteins in synaptic transmission and neural degeneration. Annu. Rev. Neurosci. 20, 125-156.
28. +. Proc. Natl. Acad. Sci. USA 89, 9074-9078.
29. + toxicity encodes a vesicular amine transporter. Cell 70, 539-551.
30. Maron, R., Stern, Y., Kanner, B.I., and Schuldiner, S. (1983). Functional asymmetry of the amine transporter from chromaffin granules. J. Biol. Chem. 258, 11476-11481.
31. Melega, W.P., Williams, A.E., Schmitz, D.A., DiStefano, E.W., and Cho, A.K. (1995). Pharmacokinetic and pharmacodynamic analysis of the actions of D-amphetamine and d-methamphetamine on the dopamine terminal. J. Pharmacol. Exp. Ther. 274, 90-96.
32. Mena, M., Khan, U., Togasaki, D.M., Sulzer, D., Epstein, C.J., and Przedborski, S. (1997). Effects of wild-type and mutated copper/zinc superoxide dismutase on neuronal survival and L-DOPA-induced toxicity in postnatal midbrain culture. J. Neurochem. 69, 21-33.
33. Merickel, A., Rosandich, P., Peter, D., and Edwards, R.H. (1995). Identification of residues involved in substrate recognition by a vesicular monoamine transporter. J. Biol. Chem. 270, 25798-25804.
34. Napolitano, A., Cesura, A.M., and Da Prada, M. (1995). The role of monoamine oxidase and catechol-O-methyltransferase in dopaminergic neurotransmission. J. Neural Transm. 45, 35-45.
35. Perlman, R.L., and Sheard, B.E. (1982). Estimation of the cytoplasmic concentrations of dopamine in pheochromocytoma cells. Biochim. Biophys. Acta 719, 334-340.
36. Peter, D., Jimenez, J., Liu, Y., Kim, J., and Edwards, R.H. (1994). The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors. J. Biol. Chem. 269, 7231-7237.
37. Peter, D., Liu, Y., Sternini, C., de Giorgio, R., Brecha, N., and Edwards, R.H. (1995). Differential expression of two vesicular monoamine transporters. J. Neurosci. 15, 6179-6188.
38. Pierce, R.C., and Kalivas, P.W. (1995). Amphetamine produces sensitized increases in locomotion and extracellular dopamine preferentially in the nucleus accumbens shell of rats administered repeated cocaine. J. Pharmacol. Exp. Ther. 275, 1019-1029.
39. Pothos, E., Desmond, M., and Sulzer, D. (1996). L-3,4-dihydroxyphenylalanine increases the quantal size of exocytotic dopamine release in vitro. J. Neurochem. 66, 629-636.
40. Rayport, S., Sulzer, D., Shi, W.-X., Sasasdikosol, S., Monaco, J., Batson, D., and Ragendran, G. (1992). Identified postnatal mesolimbic dopamine neurons in culture: morphology and electrophysiology. J. Neurosci. 12, 4264-4280.
41. Robinson, T.E. (1991). The neurobiology of amphetamine psychosis: evidence from studies with an animal model. Neurosci. Res. Suppl. 14, 185-201.
42. Rudnick, G., and Wall, S.C. (1992). The molecular mechanism of "ecstasy" [3,4-methylenedioxymethamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc. Natl. Acad. Sci. USA 89, 1817-1821.
43. Ryan, T.A., Reuter, H., Wendland, B., Schweizer, F.E., Tsien, R.W., and Smith, S.J. (1993). The kinetics of synaptic vesicle recycling measured at single presynaptic boutons. Neuron 11, 713-724.
44. 3H-Ro 19-6327 in vitro: Localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs and human brain. J. Neurosci. 12, 1977-1999.
45. Scheller, R.H. (1995). Membrane trafficking in the presynaptic nerve terminal. Neuron 14, 893-897.
46. Schuldiner, S., Shirvan, A., and Linial, M. (1995). Vesicular neurotransmitter transporters: from bacteria to humans. Physiol. Rev. 75, 369-392.
47. Schwartz, E.A. (1987). Depolarization without calcium can release gamma-aminobutyric acid from a retinal neuron. Science 238, 350-355.
48. Seiden, L.S., Sabol, K.E., and Ricaurte, G.A. (1993). Amphetamine: effects on catecholamine systems and behavior. Annu. Rev. Pharmacol. Toxicol. 32, 639-677.
49. Song, H.-J., Ming, G.-L., Fon, E., Bellocchio, E., Edwards, R.H., and Poo, M.-M. (1997). Expression of a putative vesicular acetylcholine transporter facilitates quantal transmitter packaging. Neuron 18, 815-826.
50. Spector, S., Gordon, R., Sjoerdsma, A., and Udenfriend, S. (1967). End product inhibition of tyrosine hydroxylase as a possible mechanism for regulation of norepinephrine synthesis. Mol. Pharmacol. 3, 549-555.
51. Sudhof, T.C. (1995). The synaptic vesicle cycle: a cascade of protein-protein interactions. Nature 375, 645-653.
52. Sulzer, D., and Rayport, S. (1990). Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action. Neuron 5, 797-808.
53. Sulzer, D., Maidment, N.T., and Rayport, S. (1993). Amphetamine and otherweak bases act to promote reverse transport of dopamine in ventral midbrain neurons. J. Neurochem. 60, 527-535.
54. Sulzer, D., Chen, T.-K., Lau, Y.Y., Kristensen, H., Rayport, S., and Ewing, A. (1995). Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J. Neurosci. 15, 4102-4108.
55. Sulzer, D., St. Remy, C., and Rayport, S. (1996). Reserpine inhibits amphetamine action in ventral midbrain culture. Mol. Pharmacol. 49, 338-342.
56. Thomas, S.A., Matsumoto, A.M., and Palmiter, R.D. (1995). Noradrenaline is essential for mouse fetal development. Nature 374, 643-646.
57. Weihe, E., Schafer, M.K., Erickson, J.D., and Eiden, L.E. (1994). Localization of vesicular monoamine transporter isoforms (VMAT1 and VMAT2) to endocrine cells and neurons in rat. J. Mol. Neurosci. 5, 149-164.
58. Westlund, K.N., Denney, R.M., Rose, R.M., and Abell, C.W. (1988). Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem. Neuroscience 25, 439-456.
59. Wise, R.A. (1990). The role of reward pathways in the development of drug dependence. In Psychotropic Drugs of Abuse, D.J.K. Balfour, ed. (Oxford: Pergamon), pp. 23-57.
60. Zhou, Q.Y., and Palmiter, R.D. (1996). Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic. Cell 83, 1197-1209.
61. Zhou, Q.Y., Quaife, C.J., and Palmiter, R.D. (1995). Targeted disruption of the tyrosine hydroxylase gene reveals that catecholamines are required for mouse fetal development. Nature 374, 640-643.
62. Zigmond, R.E., Schwarzschild, M.A., and Rittenhouse, A.R. (1989). Acute regulation of tyrosine hydroxylase by nerve activity and by neurotransmitters via phosphorylation. Annu. Rev. Neurosci. 12, 415-461.